Rx Bandz Secures Strategic Funding to Advance MiniJect Auto‑Injector Platform for Emergency Care

Rx Bandz, a privately held biotech and medical device company based in Locust Valley, New York, has strengthened its financial position through multiple funding arrangements and investment partnerships as it develops its next‑generation patient‑centric auto‑injector platform, MiniJect®, which is designed to deliver a wide range of emergency and life‑saving injectable medications.

In early 2025, Rx Bandz secured an initial term loan facility from Leonid Capital Partners, a firm known for providing flexible financing by leveraging government contracts as lendable assets to support early and mid‑stage innovators. This facility was structured in recognition of Rx Bandz’s receipt of significant U.S. Air Force military research grants, and the funds are intended to support the company’s preparation for an expedited FDA submission of its MiniJect auto‑injector for delivering epinephrine.

The financing from Leonid Capital Partners is part of a broader capital strategy that includes plans to pursue a Series A Preferred funding round with an aggregate target of approximately $8 million, which the term loan is helping to catalyze. Company leadership has emphasized that this funding runway allows Rx Bandz to focus on completing crucial manufacturing reliability testing and human factors studies necessary for regulatory submissions without the need for in‑vivo human clinical trials at this stage.

Later in 2025, Rx Bandz announced a second term loan facility with Leonid Capital Partners, underscoring the ongoing financial support from the investor and further enabling progress toward regulatory milestones and expanded product development. While the exact financial terms of this second facility were not disclosed, the structure again reflects Leonid’s strategy of converting government contract achievements — including more than $23 million in U.S. Air Force awards — into growth capital for development stage companies. This continued partnership signals confidence in Rx Bandz’s innovative platform and its potential impact across both military and civilian healthcare markets.

In addition to structured financing from Leonid, Rx Bandz has attracted backing from the angel investing community. In April 2024, She’s Independent, a member‑led angel investment group focused on supporting women‑owned and women‑led startups, announced an investment in the company. Although the financial terms of that investment were not made public, She’s Independent cited its interest in frontier health technologies and support for female founder Jessica Walsh as key drivers of its decision. This investment is intended to support the Rx Bandz pipeline through further research and development, clinical evaluation, and efforts to bring drug–device combinations to market for both military and civilian emergency medical applications.

Beyond private funding and investment partnerships, Rx Bandz has been the recipient of non‑dilutive funding from government sources. The company has won multiple Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) contracts from the U.S. Air Force and Department of Defense, including a Phase II SBIR contract worth approximately $1.25 million to investigate shelf‑life extension technologies for critical drugs like epinephrine, and larger multi‑million‑dollar awards for developing its auto‑injector platform for military use. These contracts not only provide financial resources but also validate the technology’s relevance to national security and battlefield medicine.

According to industry listings, Rx Bandz has raised more than $11 million in combined dilutive and non‑dilutive funding to date, reflecting the aggregate impact of military, angel and structured financing initiatives. This level of backing underscores significant investor and institutional confidence in the company’s mission to transform emergency injectable drug delivery through compact, robust, and user‑friendly devices.

Company founder and CEO Jessica Walsh has highlighted the practical and patient‑centered design of the MiniJect platform, noting its potential to improve outcomes for conditions ranging from anaphylaxis and severe allergic reactions to pain management and non‑compressible hemorrhage. The company’s capital strategy — combining external investment, strategic term loan facilities, and government contract funding — is aligned with its aggressive development timeline, including anticipated FDA submissions planned for late 2026 and beyond.

As Rx Bandz continues to advance its product pipeline with the backing of investors and federal funding, the company is positioned to make substantial strides in both civilian healthcare and military medical readiness, addressing a growing need for versatile, reliable emergency drug delivery solutions around the world.